Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 7, 2024CureusOpen Access

Prognostic Value of Liver Biomarkers in Hepatocellular Carcinoma Patients Undergoing Yttrium 90 Transarterial Radioembolization (TARE): A Retrospective Pilot Study

View Full Paper
Ask AI
Bookmark
Share

Authors

MMMaría del Pilar Bayona MolanoUniversity of MiamiMKM. KolberNorthwestern UniversityJBJuana Valentina BarreraLoyola Medicine

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Molano et al. (2024) studied this question.

synapsesocial.com/papers/68e65baeb6db6435875ea026https://doi.org/10.7759/cureus.61904
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prognostic Value of Liver Function and Tumor Burden Scores in Patients with HCC After Transarterial Radioembolization – Retrospective Single Center Analysis2026
  2. 2Efficacy and safety of Y90 radioembolization combined with targeted therapy and immunotherapy in patients with unresectable hepatocellular carcinoma: a dual-center, retrospective study2026 · 1 citations
  3. 3Predictors of good outcomes in patients with hepatocellular carcinoma (HCC) treated with transarterial radioembolization (TARE).2024 · 1 citations
  4. 4Abstract No. 552 Hepatotoxicity and Survival in Patients with Cirrhotic Hepatocellular Carcinoma versus Liver Metastatic Disease After Yttrium-90 Radioembolization2024 · 1 citations
  5. 5Hepatocellular carcinoma patients treated with TARE monotherapy or combination therapy with curative intent: a retrospective, exploratory analysis of two European prospective studies2026